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Identity 
Other names: MIRN146B, miRNA146B 
HGNC (Hugo): MIR146B 
Location: 10q24.32 
Local order: Based on Mapviewer, gene flanking 
MIR146B oriented from centromere to telomere on 
10q24.32 are: 
- NFKB2: Nuclear factor of kappa light polypeptide 
gene enhancer in B-cell 2 
- PSD: pleckstrin and Sec7 domain containing 
- FBXL15: F-box and leucine-rich repeat protein 15 
- CUEDC2: CUE domain containing 2 
- MIR146B: microRNA 146b 
- LOC100505761: hypothetical LOC100505761 
- TMEM180: transmembrane protein 180 
- ACTR1A: ARP1 actin-related protein 1 homolog A 
DNA/RNA 
Note 
The MIR146B gene is transcribed into a precursor that
produces two mature microRNAs, miR-146b-5p and 
miR-146b-3p.  
These microRNAs belong to the miR-146 family, 
which comprises 2 other members, miR-146a-5p and 
miR-146a* (recently renamed miR-146a-3p) produced 
from a gene, MIR146A, localized on chromosome 5. 
Description 
MIR146B is located in an intergenic region. 
Transcription 
RNA Polymerase II is suggested to be the most likely 
enzyme involved in microRNA transcription, leading to 
the production of a ~1000 nucleotide primary 
microRNA, in this case pri-miR-146b. The beginning 
and the end of the pri-miR-146b sequence are 
unknown. 
pre-miR-146b 
miRBase accession number: MI0003129. 






miRBase accession number: MIMAT0002809. 
Length: 22 nucleotides. 
Sequence: 5'-UGAGAACUGAAUUCCAUAGGCU-3' 
mature miR-146b-3p 
miRBase accession number: MIMAT0004766. 
Length: 22 nucleotides. 
Sequence: 5'-UGCCCUGUGGACUCAGUUCUGG-3' 
Pseudogene 
No reported pseudogenes. 
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A. Homo sapiens stem-loop structure of pre-miR-146b. This figure represents the sequence and structure of the miR-146b precursor 
(pre-miR-146b). Two different mature miRNAs are produced from this precursor: miR-146b-5p (sequence in blue) and miR-146b-3p 
(sequence in pink). The orientations 5' to 3' are indicated by the direction of the arrows. B. The miR-146 family members. Identities 
between the sequences of miR-146a-5p and miR-146b-5p are shown in orange and those between the sequences of miR-146a-3p and 
miR-146b-3p are shown in green. MiR-146a-5p and miR-146b-5p differ by only two nucleotides located outside the seed region, while 




microRNAs aren't translated into amino acids. 
Mutations 
Note 
The 1000 Genome project identified a SNV (single 
nucleotide variation) in one West African individual,  
C>T variation at position 104196269 (according to 
hg19-Feb_2009) in the first nucleotide of pre-miR-
146b.  
The minor allele frequency is 0.059 in 118 individual 
samples of a West Africa population. This variation s 
reported in the NCBI SNP database and referenced 





mir-146b-5p along with other microRNAs may permit 
to differentiate breast tumour sub-types. However, 
conflicting results have been obtained. One study, 
where miR-146b has been analysed in 167 breast 
cancer cases, showed an elevated expression in triple
negative breast tumours.  
This study comprised analyses of several different 
tumour mammary cell lines and miR-146b-5p was  
 
found to be the most expressed in basal-like tumour 
cell lines (Garcia et al., 2011). 
A second study, based on 20 samples only, identified 
specific expression of a set of seven microRNAs 
(including miR-146b-5p) in normal basal cells but not 
in basal-like breast cancers, which are close to triple 
negative breast cancers. miR-146b-5p may have an 
elevated expression in malignant myoepithelioma of 
the breast (Bockmeyer et al., 2011). 
Oncogenesis 
Two studies described a biological role for miR-146b 
in breast tumour progression.  
The BRMS1 (Breast cancer Metastasis Suppressor 1) 
protein up-regulated the expression of miR-146b in 
MDA-MB-435, a tumour mammary cell line.  
Moreover, the overexpression of this microRNA down-
regulated the expression of EGFR (Epidermal Growth 
Factor Receptor) in another tumour cell line, MDA-
MB-231. This study showed an impact, in vitro, of 
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miR-146b on invasion and migration of cells and on the 
suppression of metastasis (Bockmeyer et al., 2011). 
The second study depicted a direct target of miR-146b-
5p, BRCA1 (BReast CAncer 1), one of the two major 
breast cancer predisposition genes.  
The binding of miR-146-5p to the BRCA1 3'UTR 
decreased the expression of BRCA1, induced cellular 
proliferation and reduced the homologous 
recombination rate. miR-146b seemed to have an 
important role in tumour progression via BRCA1 
(Garcia et al., 2011). 
Thyroid cancer 
Disease 
Three studies showed that miR-146b, along with a set 
of other microRNAs, are overexpressed in tumours 
versus hyperplasic nodules or versus uncertain 
malignant potential tumours (Nikiforova et al., 2008; 
Lassalle et al., 2011; Chen et al., 2008). miR-146b is 
consistently overexpressed in both papillary and 
follicular thyroid carcinomas (Chen et al., 2008) and is 
associated with extrathyroidal invasion (Chou et al.,
2010) and with aggressive papillary thyroid carcinoma 
(Yip et al., 2011). Of note, in these two studies, miR-
146b overexpression seems correlated with BRAF 
mutations. 
Prognosis 
The expression of miR-146b and of a set of six other 
microRNAs was able to predict malignancy of thyroid 
fine needle aspiration specimens (Shen et al., 2012; 
Agretti et al., 2012). 
Oncogenesis 
In thyroid follicular cells, miR-146b-5p was shown to 
bind directly the 3'UTR of SMAD4, an important 
member of the TGF-β signalling pathway. This 
modulation of the TGF-β signal confirmed the 
oncogenic role of miR-146b-5p in thyroid cancers 
(Geraldo et al., 2012). 
Lung cancer 
Prognosis 
A microarray analysis of 61 squamous cell carcinoma 
samples versus 10 normal lung samples showed that 
miR-146b had the strongest prediction accuracy for 
stratifying Non-Small Cell Lung Cancer (NSCLC) in 
prognostic groups (Raponi et al., 2009). Another study 
completed this observation and found a significant 
reduction of a set of seven microRNAs (including miR-
146b) in serum of NSCLC patients (Heegaard et al., 
2012). 
Oncogenesis 
A study analysed the effect of miR-146b 
overexpression in A549 lung cancer cells. A 3-8-fold 
increase in the expression of pre-miR-146b did not alter 
the major cellular functions classically involved in
oncogenesis, such as proliferation, migration or 
invasiveness. This overexpression only impacted the  
ability to form colonies, perhaps because miR-146b-5p 
and miR-146b-3p may have opposing effects (Patnaik 
et al., 2011). 
Other cancers 
Note 
(like prostate, pancreas, kidney, colorectal) 
Disease 
microRNA profiling by microarrays has shown that 
miR-146b is overexpressed in many cancer types, such
as glioma (Xia et al., 2009), melanoma (Jukic et al., 
2010), oesophageal cancer (Zhao et al., 2012), bladder 
cancer (Pignot et al., 2012), colorectal cancer (Ragus  
et al., 2010) or oral cancers (Scapoli et al., 2010). miR-
146b seems to be also overexpressed in some prostate 
and colorectal cancers (Kanaan et al., 2012). 
Immunity 
Note 
Innate immunity and inflammation play an important 
role in cancer development and it is therefore 
noteworthy to mention that the miR-146 family is 
involved in these mechanisms of cell protection. Even 
if more evidence has been gathered in the case of the 
former, both miR-146a and miR-146b control Toll-like 
receptor and cytokine signaling pathways. miR-146b is 
predicted to bind the 3'UTR of the IL-1 receptor-
associated kinase 1 and TNF receptor-associated factor 
6 transcripts. The expression of MIR146B is regulated 
by NF-κB (Taganov et al., 2006). 
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